Company profile: Uvax Bio
1.1 - Company Overview
Company description
- Provider of vaccine R&D leveraging patented protein nanoparticle technology via the 1c-SApNP platform for single-component, self-assembling nanoparticles that display antigens. Offers vaccine candidates for HIV-1 (UVAX-1107 and UVAX-1197; Phase 1), COVID-19 (Uvax-2129, designed to address multiple variants), Ebola virus, and hepatitis C virus (HCV).
Products and services
- 1c-SApNP® Platform Technology: A proprietary, single-component, self-assembling protein nanoparticle platform that architects vaccines by displaying antigens for development of candidates
- COVID-19 Vaccine (Uvax-2129): A recombinant protein nanoparticle vaccine engineered to combat multiple COVID-19 variants, designed for broad variant coverage
- HIV-1 Vaccine Candidates (UVAX-1107 and UVAX-1197): Vaccine candidates targeting HIV-1, currently in Phase 1 clinical trials to evaluate safety and immunogenicity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Uvax Bio
Marinomed Biotech
HQ: Austria
Website
- Description: Provider of a moisturizing film that comforts dry eyes and helps prevent allergens, formulated with ingredients for the prevention and treatment of viral respiratory illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marinomed Biotech company profile →
Brii Biosciences
HQ: United States
Website
- Description: Provider of innovative medicines developed to improve public health in China, focusing on treatment options and preventive measures for Hepatitis B (prevention in Asia-Pacific excluding Japan), HIV therapies, NTM lung disease (Greater China rights), MDR/XDR Gram-negative bacterial infections (with Monash University), and anxiety and depressive disorders via internally discovered programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brii Biosciences company profile →
Taxis Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective pharmaceuticals focused on discovery and development of novel agents, including TXA709, an oral anti-MRSA agent targeting the FtsZ bacterial cell division protein (completed Phase I), and efflux pump inhibitors for Gram-negative MDR pathogens by inhibiting resistance efflux pumps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taxis Pharmaceuticals company profile →
Rebiotix
HQ: United States
Website
- Description: Provider of microbiome-based therapeutics targeting GI diseases, including FDA-approved REBYOTA for prevention of recurrence of Clostridioides difficile infection in adults; RBX2660, a live biotherapeutic in development for recurrent C. difficile; RBX7455, a non-frozen capsule in feasibility studies; and a Stool Donor Program supporting development of microbiome-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rebiotix company profile →
Emergent BioSolutions
HQ: United States
Website
- Description: Provider of medical countermeasures for biological and chemical threats, developing, manufacturing, and delivering products including NARCAN® Nasal Spray to rapidly reverse opioid overdose; BioThrax® and CYFENDUS™ anthrax vaccines; ACAM2000® smallpox vaccine; TEMBEXA® antiviral for smallpox; and EbangaTM therapeutic antibody for Ebola virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergent BioSolutions company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Uvax Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Uvax Bio
2.2 - Growth funds investing in similar companies to Uvax Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Uvax Bio
4.2 - Public trading comparable groups for Uvax Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →